InvestorsHub Logo
Followers 134
Posts 3738
Boards Moderated 0
Alias Born 01/28/2006

Re: Justfactsmam post# 369180

Friday, 08/06/2021 12:49:16 PM

Friday, August 06, 2021 12:49:16 PM

Post# of 402924
Nice review. At this point IPIX should continue on its prudent course of carefully and thoughtfully engaging the FDA. An example of aggressive promotion drawing the ire of the FDA can be seen with Cytodyn.

The FDA's letter to Cytodyn was a warning to all pharma companies.

https://www.fda.gov/drugs/drug-safety-and-availability/statement-leronlimab

The fallout from the FDA slap down continues to plague the company. Last week Cytodyn received subpoenas from the SEC and DOJ regarding Leronlimab's promotion.

https://seekingalpha.com/news/3724193-cytodyn-receives-sec-doj-subpoenas-related-to-leronlimab-as-a-covid-19-treatment

The above is addition to lawsuits from class action attorneys and shareholders.

https://www.fiercebiotech.com/biotech/cytodyn-shares-plummet-after-being-accused-by-fda-cherry-picking-covid-19-data

https://www.cnbc.com/2021/07/24/large-shareholder-group-calls-for-a-board-overhaul-at-pharma-company-cytodyn.html

GLTA Farrell
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News